

# British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA Study)




**Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.**

**Over 30,000 patients registered in the study since 2001.**

**NOW ACCEPTING NEW REGISTRATIONS AND FOLLOW-UP  
DATA ONLINE VIA THE NEW WEB PORTAL!**

To sign up please visit <https://bsrbr.org/database/>

## Eligibility for registration

|  |                                      |   |                       |   |   |
|--|--------------------------------------|---|-----------------------|---|---|
|  | Diagnosis of<br>Rheumatoid Arthritis |  | Aged 16 Years or over | Starting eligible<br>biologic treatment |  |
|--|--------------------------------------|---|-----------------------|---|---|

### ANTI-TNF

**HUMIRA**  
(adalimumab originator)\*

**ENBREL**  
(etanercept originator)\*

**REMICADE**  
(infliximab originator)\*

\*patients must be biologic, biosimilar & targeted therapy naive to be eligible


### BIOSIMILARS

|                                 |                                   |
|---------------------------------|-----------------------------------|
| <b>HULIO</b><br>(adalimumab)    | <b>ERELZI</b><br>(etanercept)     |
| <b>AMGEVITA</b><br>(adalimumab) | <b>BENEPALI</b><br>(etanercept)   |
| <b>HYRIMOZ</b><br>(adalimumab)  | <b>INFLECTRA</b><br>(infliximab)  |
| <b>IMRALDI</b><br>(adalimumab)  | <b>REMSIMA IV</b><br>(infliximab) |
| <b>RIXATHON</b><br>(rituximab)  | <b>REMSIMA SC</b><br>(infliximab) |
| <b>IDACIO</b><br>(adalimumab)   | <b>FLIXABI</b><br>(infliximab)    |

### OTHER TARGETED THERAPIES

|                                  |                                   |
|----------------------------------|-----------------------------------|
| <b>OLUMIANT</b><br>(baracitinib) | <b>ROACTEMRA</b><br>(tocilizumab) |
| <b>CIMZIA</b><br>(certolizumab)  | <b>KEVZARA</b><br>(sarilumab)     |
| <b>XELJANZ</b><br>(tofacitinib)  | <b>RINVOQ</b><br>(upadacitinib)   |
| <b>JYSELECA</b><br>(filgotinib)  |                                   |

Registration within  
6 months of the  
therapy start date\*



\*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

**Please contact the BSRBR-RA team with any questions**

0161 275 1652 / 7390 [biologics.register@manchester.ac.uk](mailto:biologics.register@manchester.ac.uk)